Drug recall · May 20, 2026
Buprenorphine Hydrochloride recall
Why: Crystallization; identified as Buprenorphine free base
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
- Lots / codes
Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027
- Quantity
- 34,293 vials
- Company
- ENDO USA, Inc., Rochester, MI
- Distribution
- USA Nationwide
- Initiated
- March 13, 2026 · Voluntary: Firm initiated
- Classified
- May 11, 2026
- Reported
- May 20, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.